Press Release

  • Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

    Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

    Los Angeles, CA.  August 3, 2020 – US Nuclear Corp. (OTC: UCLE) aims to combat COVID-19 and help patients and survivors of the virus by working together with MIFTEC to produce an unlimited supply of domestic, low-cost medical isotopes.

    The IAEA is supporting more than 121 countries with RT-PCR equipment, which is used to rapidly detect COVID-19 in real-time by a nuclear-derived technique and is one of the most widely used and accurate lab methods. The isotope Co-60 is also being used to sterilize medical equipment, devices, and supplies for COVID-19 professionals to ensure they are safe for use.  Co-60 irradiation is one of the quickest and effective methods for sterilizing large volumes of this equipment.

    Medical isotopes and nuclear medicine are proving to be effective in sterilizing, detecting, and fighting COVID-19 and guiding successful treatment. In addition to damaging the patient’s lungs, this virus also attacks the heart, blood vessels, liver, intestines, brain, and nervous system. It causes blood clots and sometimes strokes or seizures. Unfortunately, as a result, many of our COVID-19 survivors will need serious medical help for months or years to come.

    Medical isotopes are being used for lung diagnostics, determining the extent of the patient’s disease, and mapping the COVID-19 proteins, while others are being researched as a possible treatment for combating severe COVID-19 cases. Medical isotopes are necessary for nuclear medicine diagnostic scans to guide the physician in treating our brave survivors.


  • Help May Be On Its Way: 10% Of Worlds Population Suffers From Pain or Depression

    Help May Be On Its Way: 10% Of Worlds Population Suffers From Pain or Depression US Nuclear and Grapheton Develop Neural Technology

    Los Angeles, CA.  July 14, 2020 – US Nuclear Corp. (OTC: UCLE), working with a start-up company similar to Elon Musk’s ‘Neuralink’, Grapheton, is eager to announce how Grapheton’s neural stimulation technology can help treat chronic pain and depression.  It is estimated that 500 million people suffer chronic pain worldwide, and 300 million people suffer depression worldwide, affecting more people than any other health burden and adding to suicide and drug addiction rates. These symptoms are mentally and financially devastating to the afflicted persons and their families.  In fact, the total US economic burden of major depressive disorder is now estimated to be $210 billion per year*. Chronic pain and depression are extremely complex disorders that are incredibly hard to treat.  Fortunately, deep brain stimulation is proving to be an effective emerging treatment, and Grapheton has made several significant advances and improvements to the technology to make it even more viable.

    Deep brain stimulation involves the surgical implantation of tiny electrodes in your brain that send electrical signals to the areas of your brain where the problems (pain, depression, or movement disorders) originate.  These electrical signals regulate the brain’s activity in that region which can relieve the symptoms.

    Depression treatments can range from medications to lifestyle changes, therapy, or any combination of the above.  Unfortunately, some medications just exacerbate the problem, and some people have treatment-resistant depression. Deep brain stimulation is emerging as an effective treatment solution for chronic and resistant depression and has been reported to improve mood, alleviate depression, and lead to an increase in quality of life.


  • NASA Report to Congress on Interstellar Space Travel Includes Presentation of US Nuclear Partner Mifti’s “Star Trek” Fusion Propulsion

    NASA Report to Congress on Interstellar Space Travel Includes 36 Page Presentation of US Nuclear Partner Mifti’s “Star Trek” Fusion Propulsion

    Nasa Report To Congress On Interstellar Space Travel

    Los Angeles, CA.  June 16, 2020 – US Nuclear is excited to announce that MIFTI-MIFTEC President and Chief Scientist, Dr. Hafiz Rahman, was invited by NASA to give a presentation on his fusion energy technology at the Tennessee Valley Advanced Interstellar Propulsion Workshop (TVIW) in Wichita, Kansas.  The workshop was requested by Congress with support from TVIW to explore the top technologies that can be used for deep space travel.

    Dr. Rahman’s 36-page presentation titled “Staged Z-Pinch, A Target for Fusion and Possible Source for Interstellar Propulsion” discusses MIFTI’s latest developments.   MIFTI’s fusion generators could become the standard propulsion system for space travel, and also have the potential to provide unlimited, low-cost, clean energy for the earth, moon bases, and planetary colonization.

    Chemical-powered rockets have taken humans to the moon, sent countless missions into earth’s orbit, and have even powered long-range missions inside and outside of our solar systems, such as the Mars rovers and the Voyager probe launched in 1977 which is now in interstellar space. Speeds of almost 20,000 miles per hour seem fast and may have been adequate for traveling to the moon and even some nearby planets, but are far too slow and heavy with fuel to travel to more distant planets or the countless stars surrounding our solar system. Chemical-powered rockets in use today carry tons of fuel. Fully fueled, the 3-stage Atlas V-541 rocket with the spacecraft can weigh 1 million pounds; 80% of that weight is fuel and the superstructure of the first and second stages carry the fuel.


  • US Air Force Mach2 Code Tests US Nuclear and Mifti Progress of Producing Medical Isotopes

    US Air Force Mach2 Code Tests US Nuclear and Mifti Progress Towards Goals of Producing Medical Isotopes and Electric Power

    Los Angeles, CA.  May 12, 2020 – US Nuclear Corp. (OTC: UCLE) is excited about MIFTI’s (Magneto-Inertial Fusion Technologies, Inc.) recent progress in harnessing clean fusion energy as presented by a new article in a leading peer-reviewed fusion energy journal, AIP Physics of Plasmas.

    Below are some of the steps along the way towards producing clean, no-carbon fusion energy and medical isotopes:

      • August 2018: MIFTI Reaction Cell generates a record 10 billion neutrons per pulse on the 1 million ampere Zebra machine at the University of Nevada, Reno National Terawatt Facility (UNR/NTF) using their patented Staged Z-pinch (SZP) technology.
      • The US Air Force MACH-2 simulation code predicts that US Nuclear partners are likely to achieve 1 trillion neutrons per pulse or better on the L3 Harris 4 million ampere machine; the amount required for commercial production of radioisotopes and possibly to produce enough energy to achieve “Break Even” which is the gateway requirement for electric power production.
      • The year 2020: Plans are now underway to scale-up power for MIFTI and sister company, MIFTEC Laboratories, Inc. (for radiopharmaceuticals). Experiments on L3 Harris’s more powerful 4 million ampere devices are planned to begin this year.
      • It all comes together: MIFTI/MIFTEC have already drawn up the plans for their 10 million ampere machine, which is designed to provide significant net energy gain for the production of power and medical isotopes
      • MIFTI’s SZP thermonuclear fusion energy technology is fueled by a simple isotope of hydrogen from seawater; an environmentally safe, low-cost process for an unlimited, non-proliferating energy source.


  • US Nuclear & Grapheton Provide Significant Advances for Parkinson’s Disease Therapy

    US Nuclear & Grapheton Provide Significant Advances for Parkinson’s Disease Therapy

    Los Angeles, CA.  March 17, 2020 – The next chapter in US Nuclear’s (OTC: UCLE) brain-machine interface revolution in treating Parkinson’s Disease. Over 10 million people live with Parkinson’s Disease worldwide.  Parkinson’s Disease is a degenerative, progressive nervous system disorder that affects nerve cells in deep parts of the brain that control movement and memory. These nerve cells become impaired and/or die, thereby producing less dopamine thus ultimately causing the symptoms of Parkinson’s Disease. These symptoms include: tremors or shaking in your limbs, slowed movement, rigid muscles, impaired balance, coordination, and eventually, profound memory loss and dementia. Fortunately, advances in neurostimulation therapy, such as those made by Grapheton, have made it possible to treat this terrible disease.

    The treatment is called ‘Deep Brain Stimulation (DBS) and involves the surgical implantation of electrodes in your brain that send electrical signals to the areas responsible for body movement. The electrodes do not damage healthy brain tissue or destroy nerve cells; instead, they produce electrical impulses that regulate the abnormal impulses, including those caused by Parkinson’s.


  • US Nuclear Joins The Brain-Machine Interface Revolution

    US Nuclear Joins The Brain-Machine Interface Revolution

    Los Angeles, CA.  February 10, 2020 – US Nuclear Corp. (OTC: UCLE) recently signed a stock purchase agreement with start-up Grapheton Inc. to acquire a 40% stake in the company.

    Similar to Elon Musk’s ‘Neuralink’, Grapheton is developing and manufacturing an advanced new generation of wearable and implantable brain-machine interface devices.  Grapheton’s long-term goal is dedicated specifically to treating injuries and diseases such as spinal injuries, pain reduction, Parkinson’s Disease, epilepsy, stroke, and possibly Alzheimer’s.  Grapheton already has several pivotal and patented advantages in the field, including:

      1. Grapheton’s electrodes utilize a new carbon-based material that doesn’t corrode and can last as long as 40 years or more compared to less than five years from other providers, which is extremely important considering the invasive surgery required for installation or maintenance of the probes.
      2. A self-charging supercapacitor uses the brain’s own salty liquid environment as the power source, meaning that unlike other providers, no battery maintenance is required to reinstall a new battery while also ensuring that aging batteries will not leak any chemicals into the brain. Again, a huge advantage for reducing the surgery and maintenance required.
      3. Two-way electrical and chemical communication with brain neurons, meaning that Grapheton’s probes can not only send electrical signals, but also listen, record, and respond to the body’s electrical and chemical signals simultaneously.


  • US Nuclear Signs Agreement With China National Nuclear Corporation’s Subsidiary

    US Nuclear Signs Agreement With China National Nuclear Corporation’s Subsidiary

    Los Angeles, CA. January 21, 2020 – US Nuclear Corp. (OTC: UCLE) has signed a “Cooperation Agreement” with Dalian Zhonghe Scientific and Technological Development Co., a subsidiary of China National Nuclear Corporation (CNNC), to design, build, and mass-produce radiation detectors and systems for the growing China nuclear market.

    China is the world’s major builder of nuclear power plants, with 46 in operation, 15 under construction, and around 200 planned. Each nuclear power plant requires about $8 million worth of radiation detection equipment. Currently, around 80% of that radiation detection equipment is imported into China at a steep cost. Importing is not favorable due to the high cost and because the functionality has been customized for the country of origin and does not always fit local procedures, regulations, and language. US Nuclear aims to solve this problem.


  • US Nuclear to Present at the LD Micro Main Event (XII)

    US Nuclear to Present at the LD Micro Main Event (XII)

    LOS ANGELES, CA / ACCESSWIRE / December 4, 2019 / US Nuclear Corp. (OTC: UCLE), a leading manufacturer of radiation and chemical detection instrumentation including UAV mounted sensors, announced that it would be presenting at the 12th annual LD Micro Main Event on December 12 at 3:00 to 3:20 PM PST. Robert Goldstein, CEO of US Nuclear, will be presenting, meeting with investors, and showcasing US Nuclear’s new forensic drones for measuring chemical, biological, and radiological contamination in hazmat scenarios.

    “This year’s Main Event is our largest event to date, with 275 companies set to present and meet with investors” stated Chris Lahiji, President of LD Micro. “Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever-growing community. Investor interest in our events has also never been stronger, and that goes for our commitment to philanthropy as well.”


  • US Nuclear Joins Fight Against Widespread Toxic PFAS Chemical Pollution In Our Air And Water

    US Nuclear Joins Fight Against Widespread Toxic PFAS Chemical Pollution In Our Air And Water

    New data shows toxic PFAS contamination has been detected in almost every major city in the USA. While the EPA works on setting new regulations for PFAS, some states and members of congress have grown impatient with the progress of the EPA and have taken regulation into their own hands. 

    Los Angeles, CA. November 5, 2019 – PFAS, poly-and perfluoroalkyl substances, are also known as “forever chemicals” because they don’t break down in the environment.  Since these toxic chemicals don’t break down, they move through our food and water supply and eventually build up in our bodies over time. Due to the widespread, unregulated use of PFAS over the past several decades, nearly every American is now contaminated with PFAS, which can remain in the body for years and cause cancer, reproductive issues, and damage to the immune system, kidneys, and liver, among other concerns.

    Known for their CBRN (chemical, biological, radiological, nuclear) sensor technology, US Nuclear Corp. (OTC: UCLE) realized that one of the first steps in addressing the PFAS crisis is to determine where the exposure is coming from and limit that exposure. To this end, US Nuclear has developed a new line of portable air and water samplers that are used (by health and safety inspectors, public, industrial hygienists) to easily obtain multiple concentrated samples of PFAS from suspected air or water sources, which are then sent to a lab for detailed analysis.


  • US Nuclear Corp. Reports 172% Increase in Revenue in Second Quarter 2019

    US Nuclear Corp. Reports 172% Increase in Revenue in Second Quarter 2019 Results

    Los Angeles, CA. September 9, 2019 – US Nuclear Corp. (OTC: UCLE)

    • Sales for the three months ended June 30, 2019, were $1,530,523, an increase of $968,995 or 172% as compared to the same period in 2018
    • Gross profit was $785,933 compared to $287,799 for the same period in 2018, an increase of 173%
    • Cash increased from $969,118 to $1,393,915 for the six months ended June 30, 2019
    • Stock-based compensation was $804,131 compared to $328,320 during the same period in 2018
    • Net loss from operations ($466,019) due to stock-based compensation as the company acquires new partnerships, technology, sales and marketing consultants, and other services to facilitate company growth

    US Nuclear Corp., a leading manufacturer, and seller of advanced radiation and chemical detection instrumentation, recently announced the financial results for the second quarter ended June 30, 2019.

    “We had a very successful and productive second quarter in 2019.  Key metrics are increasing, with sales revenue up 172% from the same period last year,” commented Robert I. Goldstein, President, CEO, and Chairman of US Nuclear Corp. “Leaving out the stock-based compensation, our business operation had a dollar profit of $338,112, which is the main reason for the cash increase of $424,797.  The increase in sales revenue can be attributed to the strong sales growth of our signature products, including air quality monitors, tritium monitors, and forensic drones. Being first to market with our scientific drones allowed us to establish ourselves at the forefront of this fast-growing industry and we look forward to capitalizing on our momentum.”